325 related articles for article (PubMed ID: 26592506)
21. Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
Karter AJ; Ahmed AT; Liu J; Moffet HH; Parker MM
Diabet Med; 2005 Aug; 22(8):986-93. PubMed ID: 16026362
[TBL] [Abstract][Full Text] [Related]
22. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.
Dormandy J; Bhattacharya M; van Troostenburg de Bruyn AR;
Drug Saf; 2009; 32(3):187-202. PubMed ID: 19338377
[TBL] [Abstract][Full Text] [Related]
24. Three-year clinical outcome in type 2 diabetic patients with drug-eluting stents versus bare-metal stents with pioglitazone.
Nishio K; Hosaka M; Shigemitsu M; Kobayashi Y
Cardiovasc Revasc Med; 2011; 12(4):197-202. PubMed ID: 21489889
[TBL] [Abstract][Full Text] [Related]
25. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study.
Hall GC; McMahon AD; Carroll D; Home PD
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):305-13. PubMed ID: 22271442
[TBL] [Abstract][Full Text] [Related]
26. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
Kernan WN; Viscoli CM; Dearborn JL; Kent DM; Conwit R; Fayad P; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Stuart A; Young LH;
JAMA Neurol; 2017 Nov; 74(11):1319-1327. PubMed ID: 28975241
[TBL] [Abstract][Full Text] [Related]
27. A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study.
Pfister R; Cairns R; Erdmann E; Schneider CA
Int J Cardiol; 2013 Jan; 162(2):112-6. PubMed ID: 21636144
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Tseng CH
J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
[TBL] [Abstract][Full Text] [Related]
29. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
30. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.
Nakayama T; Komiyama N; Yokoyama M; Namikawa S; Kuroda N; Kobayashi Y; Komuro I
Int J Cardiol; 2010 Jan; 138(2):157-65. PubMed ID: 18817993
[TBL] [Abstract][Full Text] [Related]
31. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.
Schneider CA; Ferrannini E; Defronzo R; Schernthaner G; Yates J; Erdmann E
J Am Soc Nephrol; 2008 Jan; 19(1):182-7. PubMed ID: 18057215
[TBL] [Abstract][Full Text] [Related]
32. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Nissen SE; Wolski K; Topol EJ
JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
[TBL] [Abstract][Full Text] [Related]
33. Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).
Dormandy JA; Betteridge DJ; Schernthaner G; Pirags V; Norgren L;
Atherosclerosis; 2009 Jan; 202(1):272-81. PubMed ID: 18538774
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
Kaku K; Daida H; Kashiwagi A; Yamashina A; Yamazaki T; Momomura S; Iwase T; Yamasaki Y; Nagatsuka K; Kitagawa K; Kawamori R
Curr Med Res Opin; 2009 Dec; 25(12):2925-32. PubMed ID: 19835463
[TBL] [Abstract][Full Text] [Related]
35. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
36. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
[TBL] [Abstract][Full Text] [Related]
37. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
[TBL] [Abstract][Full Text] [Related]
38. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
[TBL] [Abstract][Full Text] [Related]
39. PROactive: time for a critical appraisal.
Betteridge DJ; DeFronzo RA; Chilton RJ
Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
[TBL] [Abstract][Full Text] [Related]
40. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
